Hepatitis
As featured on
CHICAGO (WAND) — The Illinois Department of Public Health (IDPH) launched a new coalition on…
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus. Chronic hepatitis B is hard to treat, and the virus can hide out in the body, making a cure elusive. Researchers reported Thursday that in two international studies, about 1 in 5 patients given the experimental drug for six months saw their virus reduced to levels low enough that the immune system could keep it in check, what scientists call a “functional cure.” The studies were funded by GSK, which is seeking regulatory approval.
